MCID: INF039
MIFTS: 47

Infratentorial Cancer

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Infratentorial Cancer

MalaCards integrated aliases for Infratentorial Cancer:

Name: Infratentorial Cancer 12 15 74
Infratentorial Neoplasms 45 74
Malignant Infratentorial Tumors 12
Brain Neoplasm, Infratentorial 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4706
MeSH 45 D015192
NCIt 51 C3139 C4966
ICD10 34 C71.7

Summaries for Infratentorial Cancer

Disease Ontology : 12 A brain cancer that is located in the infratentorial region.

MalaCards based summary : Infratentorial Cancer, also known as infratentorial neoplasms, is related to medulloblastoma and childhood infratentorial neoplasm. An important gene associated with Infratentorial Cancer is SHH (Sonic Hedgehog Signaling Molecule), and among its related pathways/superpathways are G-Beta Gamma Signaling and Gastric cancer. The drugs Bupivacaine and Fentanyl have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and nk cells, and related phenotypes are Increased Nanog expression and behavior/neurological

Related Diseases for Infratentorial Cancer

Diseases related to Infratentorial Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 87)
# Related Disease Score Top Affiliating Genes
1 medulloblastoma 28.9 ATOH1 CTNNB1 GLI1 GLI2 GLI3 KCTD11
2 childhood infratentorial neoplasm 12.3
3 holoprosencephaly, recurrent infections, and monocytosis 10.4 GLI2 PTCH1
4 vulva basal cell carcinoma 10.4 MYC PTCH1
5 septopreoptic holoprosencephaly 10.4 GLI2 PTCH1 SHH
6 midline interhemispheric variant of holoprosencephaly 10.4 GLI2 PTCH1 SHH
7 combined pituitary hormone deficiencies, genetic forms 10.4 GLI2 OTX2
8 alobar holoprosencephaly 10.4 GLI2 PTCH1 SHH
9 lobar holoprosencephaly 10.4 GLI2 PTCH1 SHH
10 desmoplastic infantile ganglioglioma 10.4 MYCN SYP
11 holoprosencephaly 4 10.4 GLI3 MYC SHH
12 semilobar holoprosencephaly 10.3 GLI2 PTCH1 SHH
13 hypothyroidism, thyroidal or athyroidal, with spiky hair and cleft palate 10.3 GLI1 GLI2 SHH
14 pleuropulmonary blastoma 10.3 MYCN SHH TP53
15 calcifying epithelial odontogenic tumor 10.3 GLI2 PTCH1 TP53
16 gastric squamous cell carcinoma 10.3 GLI1 SHH SYP
17 gastric tubular adenocarcinoma 10.3 GLI1 SHH SYP
18 agnathia-otocephaly complex 10.3 GLI2 OTX2 SHH
19 autonomic nervous system neoplasm 10.3 MYC MYCN TP53
20 microform holoprosencephaly 10.3 GLI2 PTCH1 SHH SUFU
21 adult hepatocellular carcinoma 10.3 CTNNB1 TP53
22 central nervous system benign neoplasm 10.3 MYCN SYP TP53
23 cellular ependymoma 10.3 SYP TP53
24 askin's tumor 10.3 MYC MYCN
25 holoprosencephaly 10.3 GLI2 GLI3 PTCH1 SHH
26 greig cephalopolysyndactyly syndrome 10.3 GLI2 GLI3 PTCH1 SHH
27 pallister-hall syndrome 10.3 GLI1 GLI2 GLI3 SHH
28 lung acinar adenocarcinoma 10.2 CTNNB1 MYC
29 esophageal atresia 10.2 GLI2 GLI3 MYCN SHH
30 nasopharyngeal disease 10.2 CTNNB1 MYC TP53
31 pharynx cancer 10.2 CTNNB1 MYC TP53
32 cervix disease 10.2 CTNNB1 MYC TP53
33 tracheoesophageal fistula 10.2 GLI3 MYCN SHH SYP
34 merkel cell carcinoma 10.2 ATOH1 SYP TP53
35 central nervous system primitive neuroectodermal neoplasm 10.2 NES SYP TP53
36 cerebellum cancer 10.2 ATOH1 SHH SYP TP53
37 male reproductive organ cancer 10.2 CTNNB1 MYC TP53
38 keratocystic odontogenic tumor 10.2 GLI1 PTCH1 SHH SUFU TP53
39 cerebral primitive neuroectodermal tumor 10.2 MYC MYCN SYP TP53
40 cerebral ventricle cancer 10.2 SMARCB1 SYP TP53
41 peripheral nervous system neoplasm 10.2 MYC MYCN SYP TP53
42 rhabdoid cancer 10.2 SMARCB1 SYP TP53
43 rhabdomyosarcoma 10.2 GLI1 MYCN PTCH1 TP53
44 optic nerve neoplasm 10.2 NES SYP TP53
45 pleomorphic xanthoastrocytoma 10.2 SMARCB1 SYP TP53
46 optic nerve glioma 10.2 NES SYP TP53
47 respiratory system cancer 10.2 CTNNB1 MYC TP53
48 cell type benign neoplasm 10.1 CTNNB1 SYP TP53
49 rhabdoid tumor predisposition syndrome 1 10.1 SMARCB1 SYP TP53
50 bardet-biedl syndrome 17 10.1 GLI2 PROM1 PTCH1 SHH

Graphical network of the top 20 diseases related to Infratentorial Cancer:



Diseases related to Infratentorial Cancer

Symptoms & Phenotypes for Infratentorial Cancer

GenomeRNAi Phenotypes related to Infratentorial Cancer according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased Nanog expression GR00371-A-1 8.92 ATOH1 OTX2 PPP1R12A SMARCB1

MGI Mouse Phenotypes related to Infratentorial Cancer:

47 (show all 26)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.47 ATOH1 CTNNB1 GLI1 GLI2 MYC MYCN
2 growth/size/body region MP:0005378 10.46 CTNNB1 GLI1 GLI2 GLI3 MYC MYCN
3 digestive/alimentary MP:0005381 10.45 ATOH1 CTNNB1 GLI1 GLI2 GLI3 MYC
4 cardiovascular system MP:0005385 10.44 CTNNB1 GLI3 MYC MYCN NTRK3 OTX2
5 cellular MP:0005384 10.43 ATOH1 CTNNB1 GLI1 GLI2 GLI3 MYC
6 mortality/aging MP:0010768 10.43 ATOH1 CTNNB1 GLI1 GLI2 GLI3 MYC
7 embryo MP:0005380 10.38 CTNNB1 GLI1 GLI2 GLI3 MYC MYCN
8 nervous system MP:0003631 10.38 ATOH1 CTNNB1 GLI1 GLI2 GLI3 MYC
9 craniofacial MP:0005382 10.35 CTNNB1 GLI1 GLI2 GLI3 MYC MYCN
10 homeostasis/metabolism MP:0005376 10.35 ATOH1 CTNNB1 GLI2 GLI3 MYC MYCN
11 normal MP:0002873 10.31 ATOH1 CTNNB1 GLI1 GLI2 GLI3 MYC
12 endocrine/exocrine gland MP:0005379 10.29 ATOH1 CTNNB1 GLI1 GLI2 GLI3 MYC
13 hearing/vestibular/ear MP:0005377 10.27 ATOH1 CTNNB1 GLI2 GLI3 MYC NTRK3
14 no phenotypic analysis MP:0003012 10.27 ATOH1 CTNNB1 GLI1 GLI2 GLI3 MYC
15 limbs/digits/tail MP:0005371 10.25 CTNNB1 GLI1 GLI2 GLI3 MYC MYCN
16 integument MP:0010771 10.21 ATOH1 CTNNB1 GLI2 GLI3 MYC PTCH1
17 muscle MP:0005369 10.21 CTNNB1 GLI2 MYC MYCN OTX2 PPP1R12A
18 neoplasm MP:0002006 10.15 CTNNB1 GLI1 MYC PROM1 PTCH1 SHH
19 reproductive system MP:0005389 10.1 CTNNB1 GLI1 GLI2 GLI3 MYC MYCN
20 liver/biliary system MP:0005370 10.08 CTNNB1 MYC MYCN SHH SMARCB1 SUFU
21 respiratory system MP:0005388 10.03 ATOH1 CTNNB1 GLI1 GLI2 GLI3 MYCN
22 pigmentation MP:0001186 10.01 CTNNB1 GLI3 MYC OTX2 PROM1 PTCH1
23 renal/urinary system MP:0005367 9.97 CTNNB1 GLI1 GLI3 MYCN PPP1R12A PTCH1
24 skeleton MP:0005390 9.85 CTNNB1 GLI2 GLI3 MYC MYCN OTX2
25 vision/eye MP:0005391 9.4 CTNNB1 GLI2 GLI3 MYCN NTRK3 OTX2
26 taste/olfaction MP:0005394 9.35 CTNNB1 GLI3 OTX2 PTCH1 SHH

Drugs & Therapeutics for Infratentorial Cancer

Drugs for Infratentorial Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 86)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bupivacaine Approved, Investigational Phase 3,Phase 2 2180-92-9, 38396-39-3 2474
2
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
3
Morphine Approved, Investigational Phase 2 57-27-2 5288826
4
Carboplatin Approved Phase 2 41575-94-4 38904 10339178 498142
5
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
6
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
7
Sirolimus Approved, Investigational Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616
8
Everolimus Approved Phase 2,Phase 1 159351-69-6 6442177 70789204
9
leucovorin Approved Phase 2 58-05-9 6006 143
10
Cisplatin Approved Phase 2 15663-27-1 441203 84093 2767
11
Gemcitabine Approved Phase 2 95058-81-4 60750
12
Cyclophosphamide Approved, Investigational Phase 2 6055-19-2, 50-18-0 2907
13
Epinephrine Approved, Vet_approved Phase 2 51-43-4 5816
14
Pemetrexed Approved, Investigational Phase 2 150399-23-8, 137281-23-3 60843 446556
15
Racepinephrine Approved Phase 2 329-65-7 838
16
Vincristine Approved, Investigational Phase 2 2068-78-2, 57-22-7 5978
17
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
18
Irinotecan Approved, Investigational Phase 2 100286-90-6, 97682-44-5 60838
19
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
20
Nicotinamide Approved, Investigational Phase 2 98-92-0 936
21
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
22
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
23
Nimotuzumab Investigational Phase 2 780758-10-3, 828933-61-3
24 Analgesics, Opioid Phase 2
25 Central Nervous System Depressants Phase 2
26 Peripheral Nervous System Agents Phase 2
27 Anesthetics Phase 2
28 Anesthetics, Local Phase 2
29 Narcotics Phase 2
30 Analgesics Phase 2
31 Immunologic Factors Phase 2,Phase 1
32 Immunosuppressive Agents Phase 2,Phase 1
33 Anti-Infective Agents Phase 2,Phase 1
34 Angiogenesis Modulating Agents Phase 2
35 Anti-Bacterial Agents Phase 2,Phase 1
36 Angiogenesis Inhibitors Phase 2
37 Protein Kinase Inhibitors Phase 2
38
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
39 Antibiotics, Antitubercular Phase 2,Phase 1
40 Antifungal Agents Phase 2,Phase 1
41 Antineoplastic Agents, Phytogenic Phase 2
42 Antirheumatic Agents Phase 2
43 Folic Acid Antagonists Phase 2
44
s 1 (combination) Phase 2
45 Antimitotic Agents Phase 2,Phase 1
46 Alkylating Agents Phase 2
47 Antimetabolites, Antineoplastic Phase 2
48 Epinephryl borate Phase 2
49 Nucleic Acid Synthesis Inhibitors Phase 2
50 Folate Phase 2

Interventional clinical trials:

(show all 28)
# Name Status NCT ID Phase Drugs
1 Ultrasound-guided Greater Occipital Nerve Block in Children Undergoing Posterior Fossa Craniotomy Active, not recruiting NCT03762343 Phase 3 ultrasound guided Greater occipital nerve block;control group C
2 The Effects of Scalp Block on Haemodynamic Response and Postoperative Pain in Posterior Fossa Surgery Completed NCT02852382 Phase 2 Bupivacaine;morphine patient controlled analgesia
3 Thalomid and Carboplatin for the Treatment of Pediatric Brain Stem Glioma Completed NCT00179881 Phase 2 Carboplatin;Thalomid
4 Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication Recruiting NCT02233049 Phase 2 Erlotinib;Everolimus;Dasatinib
5 A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma Recruiting NCT01878617 Phase 2 Cyclophosphamide;Cisplatin;Vincristine;Vismodegib;Pemetrexed;Gemcitabine
6 Nimotuzumab in Combination With Radio-chemotherapy for the Treatment of Brainstem Tumor in Children Recruiting NCT02672241 Phase 2 Nimotuzumab;Temozolomide
7 External Beam Radiation Therapy and Cetuximab Followed by Irinotecan and Cetuximab for Children and Young Adults With Newly Diagnosed Diffuse Pontine Tumors and High-Grade Astrocytomas Active, not recruiting NCT01012609 Phase 2
8 Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors Terminated NCT01836549 Phase 2 imetelstat sodium
9 Efficacy of Acetaminophen in Posterior Fossa Surgery Withdrawn NCT02532322 Phase 2 IV acetaminophen;normal saline
10 Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors Completed NCT01682746 Phase 1 Photofrin (porfimer sodium) & photodynamic therapy.
11 p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors Completed NCT01975116 Phase 1 azurin-derived cell-penetrating peptide p28
12 Study of Intraventricular Infusions of Autologous ex Vivo-expanded NK Cells in Children With Recurrent/Refractory Malignant Posterior Fossa Tumors of the Central Nervous System. NOAH's (New Opportunity, Advancing Hope) Protocol Recruiting NCT02271711 Phase 1
13 EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors Recruiting NCT03638167 Phase 1
14 HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors Recruiting NCT03500991 Phase 1
15 Cognitive Biomarkers in Pediatric Brain Tumor Patients Recruiting NCT02914067 Phase 1
16 Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors Recruiting NCT02780804 Phase 1 Entinostat
17 Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors Recruiting NCT02644291 Phase 1 Mebendazole
18 Phase I Rindopepimut After Conventional Radiation in Children w/ Diffuse Intrinsic Pontine Gliomas Terminated NCT01058850 Phase 1
19 A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors Withdrawn NCT01182883 Phase 1 IMC-A12;Temsirolimus
20 Cerebral Blood Circulation in Patients With Posterior Fossa Brain Tumor Unknown status NCT01476670
21 Effects of the Prone and the Sitting Positions on the Brain Oxygenation in Posterior Fossa Surgery Unknown status NCT02933749 Not Applicable
22 Cerebellum - Cognitive Outcome and Functional Connectivity Unknown status NCT01730274
23 Posterior Fossa Mutism on Quality of Life Completed NCT02048176
24 Role of Proteomics and Metallomics in Cerebral Vasospasm Following Subarachnoid Hemorrhage Completed NCT01799018
25 Impact of Cerebellar Mass Resection on Pain Processing Completed NCT02261649
26 Cerebellar Mutism Syndrome Study Recruiting NCT02300766
27 Advanced MRI for Posterior Fossa Tumours Recruiting NCT03471026
28 Vegetative Monitoring During Brainstem-associated Surgery Recruiting NCT03666507

Search NIH Clinical Center for Infratentorial Cancer

Cochrane evidence based reviews: infratentorial neoplasms

Genetic Tests for Infratentorial Cancer

Anatomical Context for Infratentorial Cancer

MalaCards organs/tissues related to Infratentorial Cancer:

42
Brain, T Cells, Nk Cells, Cerebellum

The Foundational Model of Anatomy Ontology organs/tissues related to Infratentorial Cancer:

20
The Infratentorial Region

Publications for Infratentorial Cancer

Articles related to Infratentorial Cancer:

# Title Authors Year
1
Infratentorial neoplasms, including the internal auditory canal and cerebellopontine angle regions. ( 2624770 )
1989

Variations for Infratentorial Cancer

Expression for Infratentorial Cancer

Search GEO for disease gene expression data for Infratentorial Cancer.

Pathways for Infratentorial Cancer

Pathways related to Infratentorial Cancer according to GeneCards Suite gene sharing:

(show all 24)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.97 CTNNB1 GLI1 GLI2 GLI3 PTCH1 SUFU
2
Show member pathways
12.68 CTNNB1 MYC SHH SMARCB1 TP53
3 12.53 CTNNB1 GLI1 GLI2 GLI3 MYC PTCH1
4
Show member pathways
12.47 GLI1 GLI2 GLI3 PTCH1 SHH SUFU
5 12.21 GLI1 GLI3 PPP1R12A PTCH1
6 12.14 MYC MYCN PROM1 TP53
7 12.1 CTNNB1 MYC PPP1R12A PTCH1 SHH TP53
8 12.01 CTNNB1 GLI3 MYC SHH
9 11.95 MYC NES OTX2 PROM1 SHH
10 11.88 CTNNB1 MED27 MYC TP53
11
Show member pathways
11.84 GLI1 GLI2 GLI3 PTCH1 SHH SUFU
12 11.76 CTNNB1 GLI1 GLI2 PROM1 PTCH1 SHH
13
Show member pathways
11.72 CTNNB1 GLI1 GLI2 GLI3 PTCH1 SHH
14 11.68 NES PROM1 SHH SYP
15 11.6 MYC MYCN TP53
16 11.58 MYC NTRK3 TP53
17 11.3 GLI1 GLI2 PTCH1 SHH
18 11.23 CTNNB1 MYC TP53
19
Show member pathways
11.22 GLI2 PTCH1 SHH
20 11.15 GLI1 GLI2 OTX2 SHH
21
Show member pathways
11.01 MYC OTX2 TP53
22 10.57 GLI3 SHH
23 10.5 PTCH1 SHH
24 10.26 MYC MYCN

GO Terms for Infratentorial Cancer

Cellular components related to Infratentorial Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cilium GO:0005929 9.63 GLI1 GLI2 GLI3 PROM1 PTCH1 SUFU
2 axoneme GO:0005930 9.43 GLI1 GLI2 GLI3
3 ciliary tip GO:0097542 9.26 GLI1 GLI2 GLI3 SUFU
4 ciliary base GO:0097546 8.92 GLI1 GLI2 GLI3 SUFU

Biological processes related to Infratentorial Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 86)
# Name GO ID Score Top Affiliating Genes
1 lung development GO:0030324 9.98 CTNNB1 GLI1 GLI2 GLI3 SHH
2 positive regulation of transcription, DNA-templated GO:0045893 9.96 CTNNB1 GLI1 GLI2 GLI3 MYC MYCN
3 in utero embryonic development GO:0001701 9.95 CTNNB1 GLI2 GLI3 PTCH1
4 positive regulation of neuron differentiation GO:0045666 9.94 ATOH1 GLI2 KCTD11
5 forebrain development GO:0030900 9.94 CTNNB1 GLI3 OTX2 SHH
6 negative regulation of gene expression GO:0010629 9.93 CTNNB1 MYCN SHH
7 canonical Wnt signaling pathway GO:0060070 9.93 CTNNB1 GLI1 SHH
8 pattern specification process GO:0007389 9.93 GLI2 GLI3 PTCH1 SHH
9 cellular response to drug GO:0035690 9.92 MYC PPP1R12A TP53
10 embryonic digit morphogenesis GO:0042733 9.92 CTNNB1 GLI2 GLI3 SHH
11 negative regulation of cell differentiation GO:0045596 9.91 CTNNB1 GLI3 SHH
12 embryonic limb morphogenesis GO:0030326 9.91 GLI3 PTCH1 SHH
13 inner ear development GO:0048839 9.91 ATOH1 GLI3 SHH
14 odontogenesis of dentin-containing tooth GO:0042475 9.91 CTNNB1 GLI2 GLI3 SHH
15 skin development GO:0043588 9.9 CTNNB1 SHH SUFU
16 limb development GO:0060173 9.9 CTNNB1 GLI3 SHH
17 midbrain development GO:0030901 9.9 CTNNB1 OTX2 SHH
18 mammary gland development GO:0030879 9.89 GLI2 GLI3 PTCH1
19 embryonic organ development GO:0048568 9.88 GLI3 PTCH1 SHH
20 smoothened signaling pathway GO:0007224 9.88 GLI1 GLI2 GLI3 PTCH1 SHH
21 T cell differentiation in thymus GO:0033077 9.87 CTNNB1 GLI3 SHH
22 developmental growth GO:0048589 9.87 GLI2 GLI3 SHH
23 branching morphogenesis of an epithelial tube GO:0048754 9.87 GLI2 GLI3 SHH
24 anatomical structure development GO:0048856 9.86 GLI2 GLI3 SHH
25 positive regulation of mesenchymal cell proliferation GO:0002053 9.86 CTNNB1 MYC SHH
26 anatomical structure formation involved in morphogenesis GO:0048646 9.85 GLI2 GLI3 SHH
27 renal system development GO:0072001 9.85 CTNNB1 PTCH1 SHH
28 negative regulation of smoothened signaling pathway GO:0045879 9.85 GLI3 KCTD11 PTCH1 SUFU
29 positive regulation of neuroblast proliferation GO:0002052 9.84 CTNNB1 GLI3 SHH
30 proximal/distal pattern formation GO:0009954 9.84 CTNNB1 GLI1 GLI2 GLI3
31 hindbrain development GO:0030902 9.83 CTNNB1 GLI2 SHH
32 regulation of smoothened signaling pathway GO:0008589 9.83 GLI1 GLI2 OTX2 PTCH1
33 dorsal/ventral neural tube patterning GO:0021904 9.8 GLI2 PTCH1 SHH
34 spinal cord motor neuron differentiation GO:0021522 9.8 GLI2 GLI3 PTCH1 SHH
35 smoothened signaling pathway involved in dorsal/ventral neural tube patterning GO:0060831 9.77 GLI2 GLI3 PTCH1
36 liver regeneration GO:0097421 9.77 GLI1 GLI3 PTCH1
37 digestive tract morphogenesis GO:0048546 9.76 GLI1 SHH
38 ectoderm development GO:0007398 9.76 CTNNB1 SHH
39 regulation of osteoblast differentiation GO:0045667 9.76 CTNNB1 GLI1
40 layer formation in cerebral cortex GO:0021819 9.76 CTNNB1 GLI3
41 negative thymic T cell selection GO:0045060 9.76 GLI3 SHH
42 positive regulation of alpha-beta T cell differentiation GO:0046638 9.75 GLI3 SHH
43 positive regulation of T cell differentiation in thymus GO:0033089 9.75 GLI2 SHH
44 embryonic foregut morphogenesis GO:0048617 9.75 CTNNB1 SHH
45 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.75 MYCN TP53
46 positive regulation of skeletal muscle tissue development GO:0048643 9.75 CTNNB1 SHH
47 artery development GO:0060840 9.74 GLI3 SHH
48 lung-associated mesenchyme development GO:0060484 9.74 CTNNB1 SHH
49 negative regulation of cell division GO:0051782 9.74 MYC PTCH1
50 hindgut morphogenesis GO:0007442 9.74 GLI2 GLI3 SHH

Molecular functions related to Infratentorial Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA-binding transcription factor activity, RNA polymerase II-specific GO:0000981 9.92 ATOH1 GLI1 GLI2 GLI3 MYC MYCN
2 chromatin binding GO:0003682 9.77 CTNNB1 GLI1 GLI2 GLI3 TP53
3 transcription factor binding GO:0008134 9.65 CTNNB1 GLI2 MYC SUFU TP53
4 p53 binding GO:0002039 9.58 NTRK3 SMARCB1 TP53
5 DNA-binding transcription factor activity GO:0003700 9.56 ATOH1 CTNNB1 GLI2 GLI3 MYC MYCN
6 patched binding GO:0005113 9.43 PTCH1 SHH
7 cholesterol binding GO:0015485 9.33 PROM1 PTCH1 SYP
8 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.28 ATOH1 GLI1 GLI2 GLI3 MYC MYCN
9 DNA binding GO:0003677 10.11 ATOH1 GLI1 GLI2 GLI3 MYC MYCN

Sources for Infratentorial Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....